title: Current applications of monoclonal antibodies for the therapy of hematopoietic cancers.
abstract: Recent trials of monoclonal antibodies in patients with leukemias or lymphomas have demonstrated the remarkable potency of these agents to kill tumor cells specifically and safely. New molecular biological and radiochemical techniques are also allowing rapid inroads into the remaining obstacles to this mode of therapy.
authors.affiliation: Sloan-Kettering Institute, New York, New York.
authors.forename: D A
authors.initials: DA
authors.lastname: Scheinberg
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D000922:Immunotoxins / Q000627:therapeutic use; D007938:Leukemia / Q000276:immunology / Q000532:radiotherapy / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D015202:Protein Engineering; D016499:Radioimmunotherapy; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors / Q000276:immunology; D014612:Vaccines
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D016298:Hematopoietic Cell Growth Factors; D007130:Immunoglobulin Idiotypes; D000922:Immunotoxins; D011956:Receptors, Cell Surface; D014612:Vaccines